| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 104.53 | 0.29 (+0.28%) | 67.61 - 114.95 | 3.5 million (Above Avg) |
Market data as of 4:00PM 05/22/13. Quotes are delayed by at least 15 min.
| Open | 104.26 |
|---|---|
| Previous Close | 104.24 |
| Day's Range | 103.62 - 107.40 |
| Market Cap | 78.4B |
| Avg Volume (10 Day) | 3.2M |
| Price/Earnings (Trailing 12 Mo.) | 17.6x |
| Earnings Per Share (Trailing 12 Mo.) | 5.91 |
| Dividend Yield | 0.47 (1.80%) |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Pass |
| Increased shareholder value? | Fail |
| Consistently increased owner earnings? | Pass |
| Sells at 25% discount to intrinsic value? | Pass |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Pass |
| Increased earnings over time? | Pass |
| Borrows within reasonable limits? | Fail |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
RBCC Opens Talks to Acquire Tech Innovators in $142 Billion Drug Delivery Market
Business Wire - Tuesday 05/21/2013 5:00 AM ET
Amgen To Present At The UBS Global Life Sciences Conference
PR Newswire - Thursday 05/16/2013 4:18 PM ET
Transgenomic Announces Global Availability of CRC RAScan™ Mutation Detection Test for Use in Patients with Metastatic Colorectal Cancer to Help Identify Appropriate Treatment
Business Wire - Thursday 05/16/2013 7:00 AM ET
New Analyses Identify Predictive Biomarkers For Vectibix® (Panitumumab) In Patients With Metastatic Colorectal Cancer
PR Newswire - Wednesday 05/15/2013 6:02 PM ET
Amgen Highlights Data To Be Presented At American Society of Clinical Oncology Annual Meeting
PR Newswire - Wednesday 05/15/2013 6:00 PM ET
RBCC Partner n3D Signs U.S. Distribution Agreement
Business Wire - Monday 05/13/2013 5:00 AM ET
Amgen And Zhejiang Beta Pharma Announce Planned Joint Venture In China
PR Newswire - Thursday 05/09/2013 4:08 PM ET
Amgen Announces Top-Line Results of Vectibix® (panitumumab) Phase 3 Head-to-Head Study Against Erbitux® (cetuximab) in Metastatic Colorectal Cancer
PR Newswire - Tuesday 05/07/2013 4:04 PM ET
| AMGN | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 9.61% | |
| Net Income Growth (1yr) | 495.02% | |
| Total Debt/Equity | 1.23 | |
| LT Debt/Equity | 1.23 | |
| Earnings Yield | 5.68% | |
| Price/Sales | 4.48 |
| Company | Last | Change |
|---|---|---|
| Gilead Sciences Inc | 55.93 | -0.96% |
| Biogen Idec Inc | 233.07 | +0.75% |
| Celgene Corp | 123.44 | -0.05% |
| Regeneron Pharmaceuticals Inc | 262.42 | +0.95% |
| Alexion Pharmaceuticals Inc | 100.57 | -2.05% |
Data is delayed by at least 15 min.